Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Express Scripts
Mallinckrodt
McKesson

Last Updated: August 11, 2022

LACOSAMIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Lacosamide patents expire, and when can generic versions of Lacosamide launch?

Lacosamide is a drug marketed by Fresenius Kabi Usa, Indoco, Zydus Pharms, Alkem Labs Ltd, Hetero Labs Ltd Iii, Alembic Pharms Ltd, Amneal Pharms, Glenmark Pharms Ltd, Hetero Labs Ltd V, Msn Labs Pvt Ltd, Sciegen Pharms Inc, and Sun Pharm. and is included in fourteen NDAs.

The generic ingredient in LACOSAMIDE is lacosamide. There are twenty-two drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the lacosamide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lacosamide

A generic version of LACOSAMIDE was approved as lacosamide by ALEMBIC PHARMS LTD on March 17th, 2022.

  Try it Free

Drug patent expirations by year for LACOSAMIDE
Recent Clinical Trials for LACOSAMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sherief Abd-ElsalamPhase 3
UCB Biopharma SRLPhase 2/Phase 3
University of California, Los AngelesPhase 4

See all LACOSAMIDE clinical trials

Pharmacology for LACOSAMIDE
Anatomical Therapeutic Chemical (ATC) Classes for LACOSAMIDE
Paragraph IV (Patent) Challenges for LACOSAMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIMPAT Injection lacosamide 10 mg/mL, 20 mL 022254 1 2016-06-30
VIMPAT Tablets lacosamide 50 mg, 100 mg, 150 mg, and 200 mg 022253 14 2012-10-29
VIMPAT Oral Solution lacosamide 10 mg/mL 022255 3 2012-10-29

US Patents and Regulatory Information for LACOSAMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm LACOSAMIDE lacosamide TABLET;ORAL 205031-004 Mar 17, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Msn Labs Pvt Ltd LACOSAMIDE lacosamide TABLET;ORAL 204921-003 Mar 17, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Indoco LACOSAMIDE lacosamide TABLET;ORAL 208308-003 Mar 17, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Msn Labs Pvt Ltd LACOSAMIDE lacosamide TABLET;ORAL 204921-004 Mar 17, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Indoco LACOSAMIDE lacosamide TABLET;ORAL 208308-004 Mar 17, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Fresenius Kabi Usa LACOSAMIDE lacosamide SOLUTION;INTRAVENOUS 214677-001 May 3, 2022 AP RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for LACOSAMIDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
UCB Pharma SA Vimpat lacosamide EMEA/H/C/000863
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,
Authorised no no no 2008-08-29
UCB Pharma S.A. Lacosamide UCB lacosamide EMEA/H/C/005243
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,
Authorised no no no 2019-08-26
Accord Healthcare S.L.U. Lacosamide Accord lacosamide EMEA/H/C/004443
Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.Lacosamide Accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
Authorised yes no no 2017-09-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Medtronic
McKinsey
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.